This article from the Japan Times indicates that the Japanese prefer Relenza over Tamiflu for young patients due to Taniflu-related suicides:
"Following a succession of fatal cases where teenagers leaped off buildings immediately after taking the medicine...the government is quietly encouraging the use of Relenza...for young patients""
The article also indicates that Japan is looking ahead and planning for the stockpiling of alternatives of which LANI must be a major candidate.
BTA Price at posting:
$1.41 Sentiment: Buy Disclosure: Held
